NAVINFLUORNSEFinancial Year 2023October 31, 2023

Navin Fluorine International Limited

3,987words
2turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
October 31, 2023 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai 400001 Scrip Code: 532504 Dear Sir / Madam, National Stock Exchange
Rs. 963
st Q2 FY24 & H1FY24 Operational Performance H1FY24 Performance at a glance 4 2 Y F 1 H Sales Rs. 963 Crs +17.9% Operating EBITDA Rs. 213 Crs Operating EBITDA Margin 22.1% +10.2% -155 bps Revenue
17.9%
H1FY24 Operational Performance H1FY24 Performance at a glance 4 2 Y F 1 H Sales Rs. 963 Crs +17.9% Operating EBITDA Rs. 213 Crs Operating EBITDA Margin 22.1% +10.2% -155 bps Revenue Growth (Y-o
Rs. 213
rformance H1FY24 Performance at a glance 4 2 Y F 1 H Sales Rs. 963 Crs +17.9% Operating EBITDA Rs. 213 Crs Operating EBITDA Margin 22.1% +10.2% -155 bps Revenue Growth (Y-o-Y) Speciality + 17.5% H
22.1%
ance 4 2 Y F 1 H Sales Rs. 963 Crs +17.9% Operating EBITDA Rs. 213 Crs Operating EBITDA Margin 22.1% +10.2% -155 bps Revenue Growth (Y-o-Y) Speciality + 17.5% HPP + 18.4% CDMO 18.0% • Consol
10.2%
2 Y F 1 H Sales Rs. 963 Crs +17.9% Operating EBITDA Rs. 213 Crs Operating EBITDA Margin 22.1% +10.2% -155 bps Revenue Growth (Y-o-Y) Speciality + 17.5% HPP + 18.4% CDMO 18.0% • Consolidated F
155 bps
H Sales Rs. 963 Crs +17.9% Operating EBITDA Rs. 213 Crs Operating EBITDA Margin 22.1% +10.2% -155 bps Revenue Growth (Y-o-Y) Speciality + 17.5% HPP + 18.4% CDMO 18.0% • Consolidated Financials
17.5%
Rs. 213 Crs Operating EBITDA Margin 22.1% +10.2% -155 bps Revenue Growth (Y-o-Y) Speciality + 17.5% HPP + 18.4% CDMO 18.0% • Consolidated Financials Q2FY24 Sales Built-Up (Rs. Crs) ~90-100 ~
18.4%
perating EBITDA Margin 22.1% +10.2% -155 bps Revenue Growth (Y-o-Y) Speciality + 17.5% HPP + 18.4% CDMO 18.0% • Consolidated Financials Q2FY24 Sales Built-Up (Rs. Crs) ~90-100 ~550-570 48.2
18.0%
DA Margin 22.1% +10.2% -155 bps Revenue Growth (Y-o-Y) Speciality + 17.5% HPP + 18.4% CDMO 18.0% • Consolidated Financials Q2FY24 Sales Built-Up (Rs. Crs) ~90-100 ~550-570 48.2 471.8 238.1
22.4%
Financials 6 Q2FY24 – Operating Performance Highlights Operating EBITDA Operating PBT Margin 22.4% 94 20.8% 98 Margin 17.2% 11.5% 72 54 Q2FY24 Highlights ▪ Operating EBITDA reduced by 154
20.8%
6 Q2FY24 – Operating Performance Highlights Operating EBITDA Operating PBT Margin 22.4% 94 20.8% 98 Margin 17.2% 11.5% 72 54 Q2FY24 Highlights ▪ Operating EBITDA reduced by 154 bps on acc
Guidance — 1 items
Sales lower than expected primarily due to
opening
6 Crs in Dahej on corrective measures ▪ Operating PBT higher depreciation charge and interest costs (Dahej site) in addition to the above reflects Q2FY23 Q2FY24 Q2FY23 Q2FY24 7 Business Vertical - Specialty Chemicals Revenues Q2FY24 Highlights ✓ ✓ Sales impacted due to deferral of 2 campaigns at Dahej Robust pipeline of new molecules (5 Molecules to be introduced in the next quarter – 2 at Dahej and 3 at Surat) ✓ Agro capex estimated to commission by end FY24.
Advertisement
Risks & concerns — 1 flagged
Strong order pipeline for coming quarters Pricing Pressure in Ref.
Sales lower than expected primarily due to
Speaking time
Sales lower than expected primarily due to
1
Investor Relations Advisors
1
Advertisement
Opening remarks
Sales lower than expected primarily due to
o Slower stabilization of R32 plant o Progressive ramping up post June/ July shut down in HPP plant at Dahej o Sales of a campaign in CDMO deferred to product to Q3FY24 specification and Method of Analysis change due in Speciality HPP CDMO Reported Revenues Lost Revenues Total o Production related issues in Dahej resulted in deferral of sales of 2 new products in Speciality *Consolidated Financials 6 Q2FY24 – Operating Performance Highlights Operating EBITDA Operating PBT Margin 22.4% 94 20.8% 98 Margin 17.2% 11.5% 72 54 Q2FY24 Highlights ▪ Operating EBITDA reduced by 154 bps on account of o Lost sales mentioned in previous slide o One off expense of ~Rs. 6 Crs in Dahej on corrective measures ▪ Operating PBT higher depreciation charge and interest costs (Dahej site) in addition to the above reflects Q2FY23 Q2FY24 Q2FY23 Q2FY24 7 Business Vertical - Specialty Chemicals Revenues Q2FY24 Highlights ✓ ✓ Sales impacted due to deferral of 2 campaigns at Dahej Robust pipeline of new molecules
Investor Relations Advisors
Navin Fluorine International Ltd. CIN : L24110MH1998PLC115499 Mr. Anish Ganatra Chief Financial Officer anish.ganatra@nfil.in www.nfil.in Orient Capital (a division of Link Group) Ms. Payal Dave +91 9819916314 payal.dave@linkintime.co.in Mr. Rajesh Agrawal +91 9967491495 rajesh.agrawal@linkintime.co.in www.orientcap.com
Advertisement
← All transcriptsNAVINFLUOR stock page →